Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.04 on Monday. The business has a 50-day moving average price of $0.04 and a 200 day moving average price of $0.04. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.10.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.